BASILEA N/ CH0011432447 /
| 2024-05-16 10:13:26 AM | Chg. +0.400 | Volume | Bid10:55:00 AM | Ask10:55:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 44.300CHF | +0.91% | 7,978 Turnover: 355,600.900 |
44.300Bid Size: 1,165 | 44.450Ask Size: 212 | 580.32 mill.CHF | - | 50.92 |
GlobeNewswire
7:15 AM
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
05-03
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire
04-24
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
04-09
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
04-04
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
03-11
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
02-13
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
01-19
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire
2023-12-11
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
2023-11-20
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire
2023-11-13
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire
2023-10-31
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire
2023-10-19
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
2023-10-17
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire
2023-10-02
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire
2023-09-28
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire
2022-03-08
Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...
GlobeNewswire
2022-02-15
Basilea to become a leading anti-infectives company backed by strong financial results 2021
GlobeNewswire
2022-01-24
Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications fr...
GlobeNewswire
2022-01-13
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in Chi...
GlobeNewswire
2022-01-11
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobipr...
GlobeNewswire
2022-01-10
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
